

RESEARCH ARTICLE

Open Access



Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion

Jūratė Barysienė^{1,2}, Aistė Žebrauskaitė^{1,2*} , Dovilė Petrikonytė^{1,2}, Germanas Marinskis^{1,2}, Sigita Aidietienė^{1,2} and Audrius Aidietis^{1,2}

Abstract

Background: To evaluate a diagnostic value of transoesophageal echocardiogram (TEE) in appropriately anticoagulated patients with a non-valvular atrial fibrillation (AF) and to establish possible additional indications for TEE; to evaluate the incidence of left atrial (LA) thrombi in appropriately anticoagulated patients in daily clinical practice.

Methods: This retrospective study analyses data of 432 patients who had been anticoagulated by means of oral anticoagulants (OACs) prior to planned cardioversion during the period from 2012 to 2015. Thromboembolic (TE) and bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Transthoracic and transoesophageal echocardiograms were evaluated. TE complications during 30 days after discharge were assessed.

Results: 432 patients were selected, aged from 22 to 89 years (mean 65.0 ± 11.5), 277 (64.1%) males and 155 (35.9%) females, 306 (70.8%) on warfarin and 126 (29.2%) on non-vitamin K antagonist oral anticoagulants (NOAC). Mean CHA2DS2-VASc score was 3.5 ± 1.5. TEE was performed for 120 (27.8%) patients, more frequently for patients on NOACs and for ones with III° LA enlargement.

TEE revealed LA thrombi in seven (5.8%) of the patients. In warfarin and NOACs groups thrombi were revealed in five (7.0%) and two (4.1%) patients, respectively. TEE did not reveal any thrombi in patients with normal left ventricular (LV) function; however, thrombi were found in two (6.1%) patients with slightly decreased LV function, and in five (17.9%) patients with markedly decreased LV function.

In patients with decreased left ventricular ejection fraction (LVEF) thrombi in LA were found more frequently than in patients with normal and slightly decreased LVEF (17.9% vs 2.2%, $p=0.008$). CHA2DS2-VASc score of all 7 patients was ≥ 5 . None of the patients after cardioversion had TE complications 30 days after discharge.

Conclusions: The risk of LA thrombi in patients prepared for scheduled cardioversion in line with the guidelines is low. Higher risk of thrombi was present in patients with decreased LVEF ($\leq 40\%$), CHA2DS2-VASc ≥ 5 . In order to assess more accurately indications to perform TEE for appropriately anticoagulated patients prior to scheduled cardioversion a study with larger number of patients is required.

Keywords: Atrial fibrillation, Non-vitamin K antagonist oral anticoagulants, Anticoagulation, Cardioversion, Transoesophageal echocardiogram, Thromboembolism

* Correspondence: zebrauskaite.aiste@gmail.com

¹Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Clinics, 2 Santariskių St., LT-08661 Vilnius, Lithuania

²Clinic of Cardiovascular Diseases, Faculty of Medicine, Vilnius University, 21 Čiurlionio St., LT-03101 Vilnius, Lithuania



Background

Atrial fibrillation (AF) is the most common long-lasting supraventricular arrhythmia [1]. In order to improve the condition of patients suffering from symptomatic persistent AF, restoration of sinus rhythm (SR) can be performed.

Ischemic stroke is the most common complication of AF, with the risk remaining high if prophylaxis of thromboembolic (TE) complications is not administered. AF is the cause of every fourth/fifth ischemic stroke and mortality of these strokes is two times higher in comparison with other types of ischemic stroke [1, 2].

Oral anticoagulants (OACs) may reduce the risk of AF related ischemic stroke by 60 – 80%. The risk of TE complications increases during restoration of SR [1]. The incidence of TE events in patients who were not treated with OACs before restoration of SR ranges from 5 to 7% [3], while in patients appropriately prepared for scheduled cardioversion, the incidence of these complications can be decreased to 1.0% [4, 5].

To prevent TE complications before scheduled SR restoration vitamin K antagonists (VKA) [1, 6] or non-vitamin K antagonist oral anticoagulants (NOACs) are administered [1, 6]. Transoesophageal echocardiogram (TEE) for detection of intracardiac thrombi can be performed in order to assess the efficacy of anticoagulation therapy or as an alternative for treatment with OACs [1, 6].

Furthermore, changes of pharmacogenomics of drugs action are more frequent in patients taking VKA. Actually, only two thirds of the patients on warfarin achieve the therapeutic international normalized ratio (INR) interval for > 64% of period required [7].

Therefore, the duration of preparation for scheduled cardioversion lasts from two to three months [8, 9]. The action of NOACs is stable, dosage is simple, preparation for scheduled SR restoration is shorter. On the other hand, some patients do not comply even with this simplified NOAC administering schedule [10]. This is why physicians have doubts concerning the reliability of anticoagulation before scheduled cardioversion and they perform additional TEE.

The aims of this retrospective study are to evaluate the expedience of TEE before cardioversion in patients properly anticoagulated with OACs suffering from persistent non-valvular AF; to assess the incidence of detection of intracardiac thrombi; to evaluate risk factors of thrombi formation, and to establish additional indications for administering TEE before scheduled SR restoration procedure.

What's new?

In patients with atrial fibrillation appropriately prepared with oral anticoagulants for scheduled cardioversion, risk of thromboembolic complications remains below 1.0%,

with the incidence of asymptomatic left atrium thrombi up to 7.7% [11, 12]. The aim is to establish clinical criteria of appropriately anticoagulated patients who are at higher risk of thromboembolic complications and for whom transoesophageal echocardiogram would be beneficial before sinus rhythm restoration.

The higher risk of cardiac thrombi is in patients with decreased left ventricular ejection fraction ($\leq 40\%$), CHA₂DS₂-VASc ≥ 5 .

Methods

This retrospective study was performed at the Centre of Cardiology and Angiology at Vilnius University Hospital Santariskiu Clinics and included patients who were ≥ 18 years old, suffering from non-valvular AF and who were prepared for scheduled SR restoration using OACs.

During the period from October 2012 to November 2015, 2940 patients underwent scheduled electrical cardioversion. 2987 patients underwent TEE; this number included 567 patients with persistent non-valvular AF who were prepared for direct current cardioversion (DCC) using OACs; 432 patients were properly anticoagulated and included into this study. The data were obtained from Hospital electronic database, out-patient and in-patient case files. The study was approved by local Bioethics committee.

AF without moderate or high degree stenosis of mitral valve or presence of mechanical valve prosthesis was considered to be non-valvular. Prior to scheduled cardioversion, the patients for ≥ 3 weeks used NOACs (dabigatran, rivaroxaban, apixaban) or warfarin, maintaining documented INR 2.0-3.0, for not less than 3 subsequent weeks. Individual dosing of NOAC drugs was done according to recommendations. Since it is difficult to confirm directly that patients are indeed taking NOACs properly, we considered to have patients' verbal confirmation and signature in hospital file confirming that she/he did not miss the dosage.

The following criteria were evaluated: patient age, sex, body mass index (BMI), concomitant diseases (arterial hypertension (AH), diabetes mellitus (DM), heart failure (HF), former stroke or transient ischemic attack (TIA), coronary artery disease (CAD). The risk of ischemic stroke and systemic embolism was evaluated using CHA₂DS₂-VASc scale [13], the risk of bleeding was assessed using HAS-BLED scale [14].

Left ventricular hypertrophy (LVH), size of left atrium (LA) and left ventricular ejection fraction (LVEF) were assessed using trans-thoracic echocardiography. LVH was diagnosed if interventricular septum and posterior left ventricle (LV) wall thickness equaled or exceeded 11 mm [15]. The size of LA was assessed according to atrial volume in 4-chamber view: no enlargement 22–58 ml, I° enlargement 59–68 ml, II° enlargement

69–78 ml, III° enlargement ≥ 79 ml [15]. LV systolic function was evaluated by LVEF: normal $\geq 50\%$, slightly decreased 41–49%, decreased $\leq 40\%$ [16]. TEE was performed in 120 patients. TEE was performed more frequently for patients on NOACs because of insufficient confidence and experience of physicians with these drugs, also because it was not possible to check the effect of the drug. The decision to perform TEE was made on the assumption of the physicians that expected risk of TE complications was higher. HF or III° LA enlargement, especially their combination, were considered as main factors influencing decision to perform TEE. All patients were studied using Philips iE33 ultrasound machine. All TEE images obtained in each patient were recorded as movie images on a digital media for display and evaluation in real time. TEE images of the LA and left atrium appendage (LAA) were evaluated in the horizontal (0°) plane and in the plane at rotation of the imaging sector (0° – 180°) during continuous visualization of the LAA. Thrombus was defined as an echo-dense, well-circumscribed, uniformly consistent mass with a texture different from that of the LAA wall. If thrombi were present, DCC was not performed.

All the study patients for whom scheduled DCC was performed were interviewed by phone 30 days after restoration of SR, in order to reveal TE complications.

Statistical analysis. The data were processed using SPSS 20 and Microsoft Excel software, Pearson's chi square tests were applied and standard deviations (SD) were calculated for the mean values.

Results

The total number of the patients with non-valvular AF prepared for scheduled SR restoration using OACs was 567. Appropriate anticoagulation was not achieved in 135 patients and the data of these patients were not included into subsequent analysis. Appropriate anticoagulation for scheduled DCC was achieved in 432 patients and the data of these patients were analyzed. The scheme of patients distribution is shown in Fig. 1.

The age of the patients ranged from 22 to 89 years, mean age was 65.1 ± 11.5 years. There were 277 (64.1%) male and 155 (35.9%) female patients. The mean age of male and female patients was 61.8 ± 11.9 and 70.5 ± 8.1 years, respectively.

The majority of the patients were suffering from AH (92.4%), HF (76.4%) and CAD (50.5%). Decreased LV systolic function was present in 18.3% and LA enlargement was observed in 83.1% of the patients. The distribution of the patients in accordance with demographic data, stroke, TE and bleeding risk, echocardiography findings and concomitant diseases is presented in Table 1.


Warfarin and NOACs were administered for 306 (70.8%) and 126 (29.2%) patients, respectively. In NOACs group 74 (58.7%) patients were on dabigatran, 39 (31.0%) were on rivaroxaban and 13 (10.3%) were on apixaban.

Warfarin was administered for the patients in whom the risk of TE complications and bleeding was higher (CHA2DS2-VASc 3.6 (SD ± 1.6) vs 3.4 (SD ± 1.5), $p = 0.058$); HAS-BLED ≥ 3 (5.6% vs 4.8% $p = 0.08$).

For males and elderly (>75 years) patients NOACs were administered more frequently (30.3% vs 27.1%, $p = 0.27$ and 25.4% vs 20.3%, $p = 0.27$, respectively). In patients with good LV systolic function, administration of NOACs was more frequent (61.1% vs 46.4%, $p < 0.001$) and when LV EF was $\leq 40\%$ administration of warfarin was more common (21.2% vs 11.1%, $p < 0.001$). When there was no LA enlargement, NOACs were administered more frequently (25.4% vs 13.4%, $p = 0.008$), but if LA was enlarged treatment by warfarin was usually preferred (74.6% vs 86.6%, $p = 0.008$). Patients with the history of stroke or TIA were prepared for restoration of SR with warfarin more frequently (6.9% vs 1.6%, $p = 0.013$). Almost one-third of the patients properly prepared for SR restoration ($n = 120$, 27.8%) underwent TEE before the procedure. This investigation was more frequently performed for the patients treated with NOACs ($n = 49$, 38.9% vs $n = 71$, 23.2%, $p < 0.001$). Detailed characteristics of the groups of the patients are presented in Table 2.

The total score of CHA2DS2-VASc, HAS-BLED and patient age had no influence on decision to perform TEE (see Table 3). TEE was performed more frequently for patients with enlargement of LA III° (32.5% vs 21.8%, $p = 0.01$) and suffering from HF (81.7 vs 74.4%, $p = 0.068$).

TEE revealed LA thrombi in 7 (5.8%) patients, in 5 males and 2 females (71.4% and 28.6%, respectively). In these patients SR was not restored, treatment with OACs was continued. The patients' age ranged from 44 to 84 years (mean age 64.1 ± 14.9). CHA2DS2-VASc score in these patients ranged from 5 to 7 points. Thrombi were found in 2 (6.1%) of patients with slightly decreased LV function and in 5 (17.9%) of patients with markedly decreased LV function. In patients with decreased LVEF thrombi in LA were found more frequently than in patients with normal and slightly decreased LVEF (17.9 vs 2.2%, $p = 0.008$). Decreased LV systolic function and CHA2DS2-VASc score ≥ 5 were observed in all male patients. In both female patients LV systolic function was slightly decreased and CHA2DS2-VASc score was 6. Thrombi were detected in 5 (7.0%) patients of warfarin group and in 2 patients (4.1%) of NOACs group. The duration of the preparation period for the scheduled restoration of SR in patients with LA thrombi in warfarin group was longer in comparison



with the period in NOACs group (2 – 24 months, mean 11.4 months vs 3 – 8 weeks, mean 6 weeks). A previous history of LA thrombi was found in two male patients, and SR was restored after prolonged anticoagulation and repeated TEE. After the next AF relapse, TEE revealed LA thrombi again, anticoagulation was prolonged and TEE repeated. One patient did not have LA thrombi, SR was restored and the patient is waiting for LA appendage closure. Another patient still has LA thrombi, and permanent AF was diagnosed. For other 3 patients TEE was repeated after 1 and 3 months, thrombi in LA remained and permanent AF with OAC treatment and rate control was continued. For 2 patients TEE was repeated after 1 month, thrombi in LA resolved and SR was restored, with no TE complications 30 days after cardioversion. In both groups the presence of thrombi did not depend on the grade of LA enlargement.

An interview by phone was performed 30 days after restoration of SR. There were no TE complications in patients four weeks after discharge.

Discussion

The aim of our study was to assess the diagnostic value of TEE in patients with non-valvular AF anticoagulated according to guidelines, and to establish possible additional indications for TEE and to evaluate incidence of

LA thrombi in properly anticoagulated patients in daily clinical practice. In our study this incidence is similar to other studies' data, in which thrombi in LA were found for 3.6–7.7% patients properly anticoagulated with warfarin before scheduled cardioversion [11, 12]. We found LA thrombi in 7.0% patients in warfarin group and 4.1% in NOACs group, we cannot state that risk of thromboembolism is higher in the warfarin group, because the number of these patients is small and because of mentioned selection bias. It should be noted that the number of patients on warfarin was larger and the duration of preparation for scheduled DCC of patients in whom LA thrombi were revealed lasted longer, in comparison with those in NOACs group, with duration ranging from 2 to 24 months (mean 11 months) vs 3-8 weeks (mean 6 weeks), respectively. The prolonged duration of preparation possibly had an influence on thrombi formation as well.

It is not obligatory to perform TEE for patients properly prepared for DCC by OACs [1, 6]. However, if a physician has any concerns regarding compliance to OAC treatment, or for other reasons that may influence the formation of intracardiac thrombi before scheduled DCC, it is reasonable to perform TEE [6, 17]. In RE-LY study the duration of dabigatran administration before scheduled DCC was ≥ 3 weeks. In the group of patients

Table 1 Distribution of the patients according to demographic data, echocardiography findings, stroke, thromboembolic and bleeding risk stratification, concomitant diseases

	Patients (n, %)	Warfarin group (n, %)	NOACs group (n, %)
Male	277 (64.1%)	193 (63.1%)	84 (66.7%)
Female	155 (35.9%)	113 (36.9%)	42 (33.3%)
Age, years ± SD	65.1 ± 11.5	64.6 ± 11.1	64.9 ± 12.5
CHA ₂ DS ₂ -VASc value ± SD	3.5 ± 1.5	3.6 ± 1.6	3.4 ± 1.5
HAS-BLED value ± SD	0.9 ± 0.9	1.1 ± 0.9	0.9 ± 0.9
HF	330 (76.4%)	238 (77.8%)	92 (73.0%)
AH	399 (92.4%)	280 (91.5%)	119 (94.4%)
CAD	216 (50.0%)	164 (53.6%)	52 (41.3%)
Previous stroke or TIA	23 (5.3%)	21 (6.9%)	2 (1.6%)
DM	54 (12.5%)	41 (13.4%)	13 (10.3%)
BMI 18.5 – 24.9 kg/m ²	59 (14.5%)	39 (13.5%)	20 (16.8%)
BMI 25.0 – 29.9 kg/m ²	138 (33.9%)	95 (33.0%)	43 (36.1%)
BMI ≥30 kg/m ²	209 (51.4%)	153 (53.0%)	56 (47.0%)
LVH	29 (6.7%)	19 (6.2%)	10 (7.9%)
LVEF ≥50%	219 (50.7%)	142 (46.4%)	77 (61.1%)
LVEF 41–49%	134 (31.0%)	99 (32.4%)	35 (27.8%)
LVEF ≤40%	79 (18.3%)	65 (21.2%)	14 (11.1%)
No LA enlargement	73 (16.9%)	41 (13.4%)	32 (25.4%)
I° LA enlargement	126 (29.2%)	91 (29.7%)	35 (27.8%)
II° LA enlargement	126 (29.2%)	94 (30.7%)	32 (25.4%)
III° LA enlargement	107 (24.8%)	80 (26.1%)	27 (21.4%)
Total	432 (100%)	306 (70.8%)	126 (29.2%)

BMI body mass index, *CAD* coronary artery disease, *DM* diabetes mellitus, *HF* heart failure, *LA* left atrial, *LVEF* left ventricular ejection fraction, *LVH* left ventricle hypertrophy, *NOACs* non-vitamin K antagonist oral anticoagulants, *SD* standard deviation, *TIA* transient ischemic attack

who received 110 mg of dabigatran twice daily, TEE was performed for 25.5%. LA thrombi were detected in 1.8% of these patients. In the group of patients who received 150 mg of dabigatran twice daily, TEE was performed in 24.1% of the cases and LA thrombi were detected in 1.2% of the patients [18]. In ARISTOTLE study, for patients prepared for scheduled DCC with apixaban, TEE was performed for 36.6% of the patients and no LA thrombi were found. However, the treatment duration prior to restoration of SR was long (251 ± 248 days) [19]. The question whether the treatment with NOACs lasting from 3 to 4 weeks is sufficient to prepare the patient for scheduled DCC remains an object for discussion. The study of dabigatran demonstrated that preparation for scheduled DCC for 4 weeks is safe [20] but the problem of compliance with the treatment still remains. The half-life of NOACs (about 12 hours) is markedly shorter in comparison with warfarin; therefore, missing of a dose at the appropriate time results in the rapid decrease of

Table 2 Distribution of the patients in accordance with decision to perform TEE, with demographic data, thromboembolic and bleeding risk stratification, echocardiography findings and concomitant disease

	TEE performed (n, %)	TEE not performed (n, %)
Male	77 (64.2%)	200 (64.1%)
Female	43 (35.8%)	112 (35.9%)
On warfarin	71 (23.2%)	235 (76.8%)
On NOACs	49 (38.9%)	77 (61.1%)
Mean age, years ± SD	63.5 ± 11.1	65.2 ± 11.6
CHA ₂ DS ₂ -VASc value ± SD	3.5 ± 1.5	3.6 ± 1.6
HAS-BLED value ± SD	1.1 ± 1.0	1.0 ± 0.8
HF	98 (81.7%)	232 (74.4%)
AH	113 (94.2%)	288 (91.7%)
CAD	54 (45.0%)	162 (51.9%)
Previous stroke or TIA	8 (6.7%)	15 (4.8%)
DM	16 (13.3%)	38 (12.2%)
BMI <25 kg/m ²	13 (11.1%)	47 (16.2%)
BMI 25.0 – 29.9 kg/m ²	47 (40.2%)	91 (31.4%)
BMI ≥30 kg/m ²	60 (49.6%)	152 (52.4%)
LVH	7 (5.8%)	22 (7.1%)
LVEF ≥50%	59 (49.2%)	160 (51.3%)
LVEF 41–49%	33 (27.5%)	105 (33.7%)
LVEF ≤40%	28 (23.3%)	47 (15.1%)
No LA enlargement	19 (15.8%)	54 (17.3%)
I° LA enlargement	24 (20.0%)	102 (32.7%)
II° LA enlargement	38 (31.7%)	88 (28.2%)
III° LA enlargement	39 (32.5%)	68 (21.8%)
Total	120 (27.8%)	312 (72.2%)

BMI body mass index, *CAD* coronary artery disease, *DM* diabetes mellitus, *HF* heart failure, *LA* left atrial, *LVEF* left ventricular ejection fraction, *LVH* left ventricle hypertrophy, *NOACs* non-vitamin K antagonist oral anticoagulants, *SD* standard deviation, *TEE* transoesophageal echocardiography, *TIA* transient ischemic attack

anticoagulation action. The patients comply with the treatment of NOACs better than these on warfarin, but the accuracy of use of preparations is not clear. During a one-year period of observation, 47.5% of the patients receiving NOACs compared to 40.2% of the patients on warfarin, complied with the treatment for 80% of observation period ($p < 0.001$) [10]. In order to assure appropriate use of the drug, more strict control is required. This is why additional TEE is being performed, even in patients properly prepared with OACs for planned SR restoration [1, 6, 9]. We did not find any relationship between the decision to perform TEE and the estimated CHA₂DS₂-VASc score. The age of the patient was not considered as a decisive factor to carry out TEE. Approximately half of the patients (49.2%) who underwent TEE were younger than 65 years.

Table 3 Distribution of patients who had and did not have TEE, in accordance with CHA₂DS₂-VASc and HAS-BLED risk scores

	CHA ₂ DS ₂ -VASc score								
	0	1	2	3	4	5	6	7	8
TEE was performed (n, %)	0 0%	9 7.5%	26 21.7%	23 19.2%	32 26.7%	19 15.8%	8 6.7%	3 2.5%	0 0%
TEE was not performed (n, %)	5 1.6%	21 6.7%	65 20.8%	58 18.6%	74 23.7%	55 17.6%	27 8.7%	6 1.9%	1 0.3%
	HAS-BLED score								
	0	1	2	3	4				
TEE was performed (n, %)	42 35.0%	42 35.0%	26 21.7%	7 5.8%	3 2.5%				
TEE was not performed (n, %)	95 30.4%	140 44.9%	64 20.5%	12 3.8%	1 0.3%				

TEE transoesophageal echocardiography

In our study, more than a half of the patients (55.2%) were obese (BMI ≥ 30 kg/m²). Obesity increases the risk of development of a new AF, the incidence of AF relapses and the risk of development of permanent AF. In obese patients with AF, the decrease of the weight reliably decreases the incidence of AF relapses and total duration of the episodes [21]; on the other hand, there are controversial data if obese patients with AF have an increased risk of TE events. According to our data, this factor had no influence on the incidence of AF relapses, the decision to perform TEE, or the detection of heart chamber thrombi.

Male and elderly patients received NOACs more frequently in our study. Warfarin was more frequently administered to the patients with a higher risk of TE complications and history of stroke or TIA. The incidence of NOACs administration was higher for patients with normal systolic LV function, without LA enlargement, while patients with decreased LVEF or LA enlargement received warfarin more frequently.

The majority of patients (73.9%; $p = 0.087$) with a high risk of bleeding (HAS-BLED ≥ 3) used warfarin. For patients who had a high TE risk (CHA₂DS₂-VASc ≥ 6) only warfarin was administered. Warfarin was more frequently administered to the patients suffering from CAD, possibly because of ESC 2015 Guidelines recommending exclusive prescription of warfarin as a part of triple anticoagulation therapy after acute coronary syndromes or scheduled percutaneous transluminal coronary angioplasty. TEE was performed in NOACs group more frequently, in comparison with the warfarin group (38.9 vs 23.2%).

In the study performed by Zylla et al. [17] 643 patients with non-valvular AF and prepared for scheduled DCC by VKA and NOACs were evaluated. TEE was performed for all study subjects. The mean CHA₂DS₂-VASc score was 4. LA thrombi were detected in 10.6% of the patients and the incidence of thrombi was higher in the warfarin group (17.8 vs 3.9%). In patients for

whom TEE revealed thrombi they had a higher CHA₂DS₂-VASc score (4–5 points in 49%), larger LA or suffered from LV systolic dysfunction. The incidence of thrombi detected was higher in patients treated by VKA with intra-cardiac devices (pacemakers, defibrillators), suffering from CAD. The patients in NOACs group were younger, had a lower CHA₂DS₂-VASc score, less dilated LA, and better LV systolic function; the incidence of NOACs administration was lower for patients with intra-cardiac devices implanted. The data of our study are quite similar. LA thrombi were revealed in 7 (5.8%) of patients properly prepared using OACs for SR restoration. We found out that the mean CHA₂DS₂-VASc score was 3.5, but the sample of patients with 4 points was the largest (24.5%). In the case when the CHA₂DS₂-VASc score was ≥ 6 , only warfarin was administered. The patients on NOACs were younger in our study and they also had less concomitant diseases. However, in patients >75 years old NOACs were administered more frequently, possibly because of difficulties in monitoring INR while administering warfarin, and INR lability.

Similarly, to the data of Zylla et al. [17], in our study the incidence of LA thrombi was higher in warfarin group. Patients in whom intracardiac thrombi were revealed had a higher CHA₂DS₂-VASc score, and decreased LV systolic function. In two patients who had history of LA thrombi TEE revealed newly formed ones. Both of these patients were on warfarin and their CHA₂DS₂-VASc score was 6.

The risk of TE complications in the event of markedly decreased LV systolic function (LV EF < 35%) in females is two times higher, in comparison with the risk in males [22]. However, the incidence of thrombi in males, according to our data, is two times higher.

In our study, an interview by phone 30 days after restoration of SR showed no TE complications.

This retrospective study was based on everyday clinical practice and demonstrated that even for patients properly prepared for SR restoration, TEE was performed quite

extensively. The risk of thrombi formation, when the patient is prepared by OACs for restoration of SR and adequate anticoagulation is achieved, is low but still remains. Therefore, in all cases the risk for a patient should be evaluated individually.

Limitations

The number of patients in whom LA thrombi have been identified is small ($n = 7$). It is necessary to perform larger studies of properly anticoagulated patients to make firm conclusions.

Conclusions

The risk of LA thrombi in patients who are prepared for scheduled SR restoration according to guidelines is low. The higher risk of cardiac thrombi was present in patients with decreased LVEF ($\leq 40\%$), CHA₂DS₂-VASc ≥ 5 . A larger number of patients is required, in order to assess more precise TEE indications for properly anticoagulated patients prior to scheduled cardioversion.

Abbreviations

AF: Atrial fibrillation; AH: Arterial hypertension; BMI: Body mass index; CAD: Coronary artery disease; DCC: Direct current cardioversion; DM: Diabetes mellitus; HF: Heart failure; INR: International normalized ratio; LA: Left atrium; LAA: Left atrial appendage; LV: Left ventricle; LVEF: Left ventricular ejection fraction; LVH: Left ventricular hypertrophy; NOAC: Non-vitamin K antagonist oral anticoagulants; OACs: Oral anticoagulants; SD: Standard deviation; SR: Sinus rhythm; TE: Thromboembolic; TEE: Transoesophageal echocardiogram; TIA: Transient ischemic attack; VKA: Vitamin K antagonists

Acknowledgements

None.

Funding

No funding was received to carry out this study.

Availability of data and materials

The data on selected patients was acquired from out-patient and in-patient case-files stored at the Vilnius University Hospital Santariskiu Clinics electronic database. All the patients under study who had had a routine scheduled cardioversion carried out, were interviewed 30 days after the restoration of sinus rhythm, in order to find out about possible thromboembolic complications. The data was processed using SPSS 20 and Microsoft Excel software. The datasets used and/or analysed during the current study are available from the corresponding author on a judicious request.

Authors' Contributions

The study conception and design – JB, GM, AA. Acquisition of data – AZ, DP. Analysis and interpretation of data – JB, AZ, AA. Drafting of the manuscript – JB, AZ, AA, GM. Critical revision – GM, AA. All the participants have made themselves familiar with the manuscript and gave their approval of the final draft of the manuscript.

Competing interests

The authors declare they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The data were obtained from hospital electronic database, out-patient and in-patient case files. The study was approved by local Bioethics committee. The data were obtained from out-patient and in-patient case-files stored at

the electronic database of the Vilnius University hospital Santariskiu Clinics. The study was approved by Vilnius University Santariskiu Clinics Local Bioethics Committee, on April 10th 2014. Protocol number EK-19.

Received: 25 October 2016 Accepted: 16 February 2017

Published online: 23 February 2017

References

- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893–962.
- Vidaillat H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. *Am J Med*. 2002;113(5):365–70.
- Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of Nonrheumatic Atrial Fibrillation. *Circulation*. 1995;92(2):160–3.
- Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. *J Am Coll Cardiol*. 1992;19(4):851–5.
- Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. *Am J Cardiol*. 1969;23(2):208–16.
- Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol*. 2015;17(10):1467–507.
- Shafeeq H, Tran TH. New Oral Anticoagulants for Atrial Fibrillation. *Pharm Ther*. 2014;39(1):54–64.
- Bushoven P, Linzbach S, Vamos M, Hohnloser SH. Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. *Arrhythmia Electrophysiol Rev*. 2015;4(1):44–6.
- Ryman J, Frick M, Frykman V, Rosenqvist M. Duration of warfarin sodium therapy prior to electrical cardioversion of atrial fibrillation. *J Intern Med*. 2003;253(1):76–80.
- Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. *J Am Heart Assoc*. 2016;5(2), e003074.
- Seidl K, Rameken M, Drögemüller A, Vater M, Brandt A, Schwacke H, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. *J Am Coll Cardiol*. 2002;39(9):1436–42.
- Fukuda S, Watanabe H, Shimada K, Aikawa M, Kono Y, Jisso S, et al. Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation. *J Cardiol*. 2011;58(3):266–77.
- Lip GYH, Nieuwlaet R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137(2):263–72.
- Pisters R, Lane DA, Nieuwlaet R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010;138(5):1093–100.
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17(4):412.
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2016;37(8):2129–200.
- Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. *Am J Cardiol*. 2015;115(5):635–40.
- Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. *Circulation*. 2011;123(2):131–6.
- Flaker G, Lopes RD, Al-Khatib SM, Hermsillo AG, Hohnloser SH, Tinga B, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial

fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). *J Am Coll Cardiol*. 2014;63(11):1082–7.

20. Johansson A-K, Juhlin T, Engdahl J, Lind S, Hagwall K, Rorsman C, et al. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? *Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol*. 2015;17(10):1514–7.
21. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. *JAMA*. 2013;310(19):2050–60.
22. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction Trials. *J Am Coll Cardiol*. 1997;29(5):1074–80.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

